SCHEMBL1593665

SCHEMBL1593665

Nc1cnc2[nH]nc(-c3ccc(Cl)cc3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.42
MKNK2 Q9HBH9 1/20 0.42
KIT P10721 1/20 0.41
ALPL P05186 1/20 0.39
MAP2K4 P45985 2/20 0.38
IKBKB O14920 1/20 0.37
MAP3K14 Q99558 1/20 0.37
CCNT1 O60563 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK9 P50750 1/20 0.37
HTR1D P28221 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR1E P28566 1/20 0.37
HTR7 P34969 1/20 0.37
HTR2B P41595 1/20 0.37
HTR6 P50406 1/20 0.37
LTA4H P09960 1/20 0.37
FGFR1 P11362 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1592860 0.84 KIT (0.49) KITMAP2K4CCNT1CCNA2CDK2
SCHEMBL1592857 0.84 ALDH1A1 (0.46) MKNK2ALPLMAP2K4CDK2MAP4K4
SCHEMBL1592922 0.84 NUDT1 (0.47) HTR7MAP4K4
SCHEMBL1593076 0.82 TRPA1 (0.45) KITMAP2K4FGFR1MAP4K4
SCHEMBL1592841 0.81 MAP2K4 (0.45) MKNK1MKNK2KITMAP2K4CCNT1
SCHEMBL29930500 0.81 DYRK1A (0.47) KITCDK2
SCHEMBL6055040 0.78 MKNK1 (0.41) MKNK1MKNK2ALPLMAP2K4HTR1D
SCHEMBL1592725 0.76 CLK1 (0.37) MKNK1KITMAP2K4MAP4K4
SCHEMBL1593552 0.75 ADORA2A (0.46) MKNK1MAP2K4CCNT1CCNA2CDK2
SCHEMBL4006856 0.74 AXL (0.55) MKNK1MKNK2MAP2K4CDK2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265610-A1 PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS Array Biopharma, Inc. (US) 2010-12-29 EP claimed
WO-2009111279-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-09-11 WO claimed
US-8394795-B2 Pyrazole [3, 4-B] pyridine Raf inhibitors ARRAY BIOPHARMA INC. (US) 2013-03-12 US disclosed
EP-2265610-B1 PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC (US) 2012-12-12 EP disclosed
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS BRAF, RAF1, ARAF MKNK1 294/4885MKNK2 360/4885KIT 1128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.